Karmustin Teva (Carmustine)

Carmustine belongs to the nitrosourea class of alkylating agents. It forms covalent bonds with DNA, creating interstrand cross‑links that block replication and transcription. This DNA damage triggers programmed cell death (apoptosis) in rapidly dividing cancer cells, while relatively sparing normal, non‑dividing tissues.

The exact dose of Karmustin is determined by the prescribing oncologist based on the patient’s diagnosis, body surface area, renal and hepatic function, and treatment protocol. Dosing is individualized and should follow the specific chemotherapy regimen outlined by the treating physician.

Carmustine is classified as contraindicated in pregnancy because it can cross the placenta and cause fetal harm. It is also excreted in breast milk and may affect a nursing infant. Women of child‑bearing potential should use effective contraception, and breastfeeding should be avoided during treatment.

To request Karmustin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Carmustine is a nitrosourea, distinguished by its ability to cross the blood‑brain barrier, making it especially useful for primary brain tumours. Compared with other alkylators such as cyclophosphamide, carmustine has a higher risk of pulmonary toxicity but offers superior central nervous system penetration.

Karmustin should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

Karmustin is supplied as an intravenous solution that is administered by a qualified healthcare professional. The infusion is typically given over a period of 30‑60 minutes, depending on the protocol, and may be followed by a flush of normal saline to ensure complete delivery of the drug.

The most serious risks include severe pulmonary toxicity (interstitial pneumonitis or fibrosis), profound myelosuppression leading to infection or bleeding, hepatic dysfunction, and rare secondary malignancies. Patients should be monitored closely for respiratory symptoms, blood count changes, and liver enzyme elevations throughout treatment.

Karmustin is contraindicated in patients with known hypersensitivity to carmustine or other nitrosoureas, those with pre‑existing severe pulmonary disease, uncontrolled infections, or significant bone‑marrow failure. Caution is also advised for individuals with impaired liver or kidney function, and it should not be used during pregnancy or lactation.